The diagnosis and management of lipodystrophy syndromes: A multi-society practice guideline

Rebecca J. Brown, David Araujo-Vilar, Pik To Cheung, David Dunger, Abhimanyu Garg, Michelle Jack, Lucy Mungai, Elif A. Oral, Nivedita Patni, Kristina I. Rother, Julia Von Schnurbein, Ekaterina Sorkina, Takara Stanley, Corinne Vigouroux, Martin Wabitsch, Rachel Williams, Tohru Yorifuji

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Objective: Lipodystrophy syndromes are extremely rare disorders of deficient body fat associated with potentially serious metabolic complications, including diabetes, hypertriglyceridemia, and steatohepatitis. Due to their rarity, most clinicians are not familiar with their diagnosis and management. This practice guideline summarizes the diagnosis and management of lipodystrophy syndromes not associated with HIV or injectable drugs. Participants: Seventeen participants were nominated by worldwide endocrine societies or selected by the committee as content experts. Funding was via an unrestricted educational grant from Astra Zeneca to the Pediatric Endocrine Society. Meetings were not open to the general public. Evidence: A literature review was conducted by the committee. Recommendations of the committee were graded using the system of the American Heart Association. Expert opinion was used when published data were unavailable or scarce. Consensus Process: The guideline was drafted by committee members and reviewed, revised, and approved by the entire committee during group meetings. Contributing societies reviewed the document and provided approval. Conclusions: Lipodystrophy syndromes are heterogeneous and are diagnosed by clinical phenotype, supplemented by genetic testing in certain forms. Patients with most lipodystrophy syndromes should be screened for diabetes, dyslipidemia, and liver, kidney, and heart disease annually. Diet is essential for the management of metabolic complications of lipodystrophy. Metreleptin therapy is effective for metabolic complications in hypoleptinemic patients with generalized lipodystrophy and selected patients with partial lipodystrophy. Other treatments not specific for lipodystrophy may be helpful as well (eg, metformin for diabetes, and statins or fibrates for hyperlipidemia). Oral estrogens are contraindicated.

Original languageEnglish (US)
Pages (from-to)4500-4511
Number of pages12
JournalJournal of Clinical Endocrinology and Metabolism
Volume101
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Lipodystrophy
Medical problems
Practice Guidelines
Fibric Acids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pediatrics
Metformin
Nutrition
Liver
Estrogens
Fats
Congenital Generalized Lipodystrophy
Committee Membership
Training Support
Testing
Group Processes
Hypertriglyceridemia
Pharmaceutical Preparations
Expert Testimony
Kidney Diseases

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

The diagnosis and management of lipodystrophy syndromes : A multi-society practice guideline. / Brown, Rebecca J.; Araujo-Vilar, David; Cheung, Pik To; Dunger, David; Garg, Abhimanyu; Jack, Michelle; Mungai, Lucy; Oral, Elif A.; Patni, Nivedita; Rother, Kristina I.; Von Schnurbein, Julia; Sorkina, Ekaterina; Stanley, Takara; Vigouroux, Corinne; Wabitsch, Martin; Williams, Rachel; Yorifuji, Tohru.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 101, No. 12, 01.12.2016, p. 4500-4511.

Research output: Contribution to journalArticle

Brown, RJ, Araujo-Vilar, D, Cheung, PT, Dunger, D, Garg, A, Jack, M, Mungai, L, Oral, EA, Patni, N, Rother, KI, Von Schnurbein, J, Sorkina, E, Stanley, T, Vigouroux, C, Wabitsch, M, Williams, R & Yorifuji, T 2016, 'The diagnosis and management of lipodystrophy syndromes: A multi-society practice guideline', Journal of Clinical Endocrinology and Metabolism, vol. 101, no. 12, pp. 4500-4511. https://doi.org/10.1210/jc.2016-2466
Brown, Rebecca J. ; Araujo-Vilar, David ; Cheung, Pik To ; Dunger, David ; Garg, Abhimanyu ; Jack, Michelle ; Mungai, Lucy ; Oral, Elif A. ; Patni, Nivedita ; Rother, Kristina I. ; Von Schnurbein, Julia ; Sorkina, Ekaterina ; Stanley, Takara ; Vigouroux, Corinne ; Wabitsch, Martin ; Williams, Rachel ; Yorifuji, Tohru. / The diagnosis and management of lipodystrophy syndromes : A multi-society practice guideline. In: Journal of Clinical Endocrinology and Metabolism. 2016 ; Vol. 101, No. 12. pp. 4500-4511.
@article{f07aad7728444da08aaf46e9db926de3,
title = "The diagnosis and management of lipodystrophy syndromes: A multi-society practice guideline",
abstract = "Objective: Lipodystrophy syndromes are extremely rare disorders of deficient body fat associated with potentially serious metabolic complications, including diabetes, hypertriglyceridemia, and steatohepatitis. Due to their rarity, most clinicians are not familiar with their diagnosis and management. This practice guideline summarizes the diagnosis and management of lipodystrophy syndromes not associated with HIV or injectable drugs. Participants: Seventeen participants were nominated by worldwide endocrine societies or selected by the committee as content experts. Funding was via an unrestricted educational grant from Astra Zeneca to the Pediatric Endocrine Society. Meetings were not open to the general public. Evidence: A literature review was conducted by the committee. Recommendations of the committee were graded using the system of the American Heart Association. Expert opinion was used when published data were unavailable or scarce. Consensus Process: The guideline was drafted by committee members and reviewed, revised, and approved by the entire committee during group meetings. Contributing societies reviewed the document and provided approval. Conclusions: Lipodystrophy syndromes are heterogeneous and are diagnosed by clinical phenotype, supplemented by genetic testing in certain forms. Patients with most lipodystrophy syndromes should be screened for diabetes, dyslipidemia, and liver, kidney, and heart disease annually. Diet is essential for the management of metabolic complications of lipodystrophy. Metreleptin therapy is effective for metabolic complications in hypoleptinemic patients with generalized lipodystrophy and selected patients with partial lipodystrophy. Other treatments not specific for lipodystrophy may be helpful as well (eg, metformin for diabetes, and statins or fibrates for hyperlipidemia). Oral estrogens are contraindicated.",
author = "Brown, {Rebecca J.} and David Araujo-Vilar and Cheung, {Pik To} and David Dunger and Abhimanyu Garg and Michelle Jack and Lucy Mungai and Oral, {Elif A.} and Nivedita Patni and Rother, {Kristina I.} and {Von Schnurbein}, Julia and Ekaterina Sorkina and Takara Stanley and Corinne Vigouroux and Martin Wabitsch and Rachel Williams and Tohru Yorifuji",
year = "2016",
month = "12",
day = "1",
doi = "10.1210/jc.2016-2466",
language = "English (US)",
volume = "101",
pages = "4500--4511",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "12",

}

TY - JOUR

T1 - The diagnosis and management of lipodystrophy syndromes

T2 - A multi-society practice guideline

AU - Brown, Rebecca J.

AU - Araujo-Vilar, David

AU - Cheung, Pik To

AU - Dunger, David

AU - Garg, Abhimanyu

AU - Jack, Michelle

AU - Mungai, Lucy

AU - Oral, Elif A.

AU - Patni, Nivedita

AU - Rother, Kristina I.

AU - Von Schnurbein, Julia

AU - Sorkina, Ekaterina

AU - Stanley, Takara

AU - Vigouroux, Corinne

AU - Wabitsch, Martin

AU - Williams, Rachel

AU - Yorifuji, Tohru

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Objective: Lipodystrophy syndromes are extremely rare disorders of deficient body fat associated with potentially serious metabolic complications, including diabetes, hypertriglyceridemia, and steatohepatitis. Due to their rarity, most clinicians are not familiar with their diagnosis and management. This practice guideline summarizes the diagnosis and management of lipodystrophy syndromes not associated with HIV or injectable drugs. Participants: Seventeen participants were nominated by worldwide endocrine societies or selected by the committee as content experts. Funding was via an unrestricted educational grant from Astra Zeneca to the Pediatric Endocrine Society. Meetings were not open to the general public. Evidence: A literature review was conducted by the committee. Recommendations of the committee were graded using the system of the American Heart Association. Expert opinion was used when published data were unavailable or scarce. Consensus Process: The guideline was drafted by committee members and reviewed, revised, and approved by the entire committee during group meetings. Contributing societies reviewed the document and provided approval. Conclusions: Lipodystrophy syndromes are heterogeneous and are diagnosed by clinical phenotype, supplemented by genetic testing in certain forms. Patients with most lipodystrophy syndromes should be screened for diabetes, dyslipidemia, and liver, kidney, and heart disease annually. Diet is essential for the management of metabolic complications of lipodystrophy. Metreleptin therapy is effective for metabolic complications in hypoleptinemic patients with generalized lipodystrophy and selected patients with partial lipodystrophy. Other treatments not specific for lipodystrophy may be helpful as well (eg, metformin for diabetes, and statins or fibrates for hyperlipidemia). Oral estrogens are contraindicated.

AB - Objective: Lipodystrophy syndromes are extremely rare disorders of deficient body fat associated with potentially serious metabolic complications, including diabetes, hypertriglyceridemia, and steatohepatitis. Due to their rarity, most clinicians are not familiar with their diagnosis and management. This practice guideline summarizes the diagnosis and management of lipodystrophy syndromes not associated with HIV or injectable drugs. Participants: Seventeen participants were nominated by worldwide endocrine societies or selected by the committee as content experts. Funding was via an unrestricted educational grant from Astra Zeneca to the Pediatric Endocrine Society. Meetings were not open to the general public. Evidence: A literature review was conducted by the committee. Recommendations of the committee were graded using the system of the American Heart Association. Expert opinion was used when published data were unavailable or scarce. Consensus Process: The guideline was drafted by committee members and reviewed, revised, and approved by the entire committee during group meetings. Contributing societies reviewed the document and provided approval. Conclusions: Lipodystrophy syndromes are heterogeneous and are diagnosed by clinical phenotype, supplemented by genetic testing in certain forms. Patients with most lipodystrophy syndromes should be screened for diabetes, dyslipidemia, and liver, kidney, and heart disease annually. Diet is essential for the management of metabolic complications of lipodystrophy. Metreleptin therapy is effective for metabolic complications in hypoleptinemic patients with generalized lipodystrophy and selected patients with partial lipodystrophy. Other treatments not specific for lipodystrophy may be helpful as well (eg, metformin for diabetes, and statins or fibrates for hyperlipidemia). Oral estrogens are contraindicated.

UR - http://www.scopus.com/inward/record.url?scp=85003601739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003601739&partnerID=8YFLogxK

U2 - 10.1210/jc.2016-2466

DO - 10.1210/jc.2016-2466

M3 - Article

C2 - 27710244

AN - SCOPUS:85003601739

VL - 101

SP - 4500

EP - 4511

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 12

ER -